Onyx receives FDA approval for Kyprolis to treat multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that its partner, Onyx Pharmaceuticals, Inc., received U.S. Food and Drug Administration (FDA) approval for Kyprolis™ (carfilzomib) for the treatment of patients with multiple myeloma who have received at least two prior therapies, including Velcade (bortezomib) for Injection and an immunomodulatory agent, such as Thalomid (thalidomide) or Revlimid (lenalidomide), and have demonstrated disease progression on or within 60 days of completion of the last therapy. The approval of Kyprolis is based on response rate.

The MMRF's affiliate organization, the Multiple Myeloma Research Consortium (MMRC), a clinical trials network of 16 leading multiple myeloma centers in North America, has bolstered the clinical development of Kyprolis for the past six years, providing clinical trial support and resources, including driving accrual to the pivotal Phase IIb trial (003-A1) that supported the accelerated approval of the treatment.

"The approval of Kyprolis is an immensely important milestone for the multiple myeloma patient community, which continues to face significant unmet need in terms of safe and effective treatments for advanced disease. While we have seen tremendous progress in the past decade, multiple myeloma remains incurable," stated Kathy Giusti, Founder and CEO of the MMRF and MMRC and a multiple myeloma patient. "We commend the FDA and Onyx for their dedication to enabling patient access to Kyprolis, and are proud of our long-term and continued partnership with Onyx throughout the development of this critical new treatment."

In 2006, the MMRF identified Kyprolis as a promising new treatment for advanced multiple myeloma during its development by Proteolix, Inc. (acquired by Onyx in 2009), and entered into a collaboration to support the therapy's development. Since that time, the MMRF has provided integral support to advance its clinical development, including:

  • Facilitating early Phase I clinical trials and three Phase II trials with Kyprolis within the MMRC network, including: the pivotal Phase IIb trial (003-A1) that supported its approval by the FDA, the original Phase II trial (003), and the Phase II trial (004) in patients who had relapsed after one to three prior therapies. Today, three combination trials involving Kyprolis are ongoing within the MMRC, including a Phase II trial for newly diagnosed patients and two Phase I trials evaluating the drug in combination with other investigational agents.
  • Providing Onyx access to the MMRC network of clinical experts, securing trial investigators, supplying centralized contracts, providing guidance on site selection and protocol design, and accruing patients to ensure that clinical work was done in the most high-quality and efficient way possible to benefit patients.
  • Raising awareness and driving enrollment to ASPIRE, Onyx's pivotal Phase III clinical trial with Kyprolis, which is now fully enrolled, and informing the entire multiple myeloma community on emerging data from clinical trials, involving Kyprolis.
  • Partnering with Onyx on the Carfilzomib Myeloma Access Program (C-MAP), an Expanded Access program that made carfilzomib available to hundreds of eligible patients in the U.S. before FDA approval.

"Over the past five years, through C-MAP and trials facilitated by the MMRC, in partnership with Proteolix and Onyx, the MMRF facilitated access to Kyprolis to more than 500 patients, many of whom had exhausted all available treatment options," stated Walter M. Capone, Chief Operating Officer of the MMRF and MMRC. "Beyond these studies and programs, Onyx has shown a deep commitment to the multiple myeloma community through its extensive clinical development program. We are very much looking forward to the opportunity for a much broader group of patients, particularly those with the greatest unmet need, to access this breakthrough therapy."

Source: Multiple Myeloma Research Foundation (MMRF)    


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Inulin gel-based oral immunotherapy is effective in suppressing food allergy responses and anaphylactic shock